Table 3.
High-dose methylprednisolone with or without rituximab in the treatment of CLL.
| Treatment Regimen | Pt No. | ORR% | CR% | PFS (median) | Study | Response in TP53 |
|---|---|---|---|---|---|---|
| HDMP (1 g/m2 × 5, q28d) | 25 | 77 | 0 | 12 months | Thornton, 2003 | 50% (10 patients) |
| HDMP 1 g/m2 × 5d (2-6 cycles) | 12 | 83 | 25 | Not achieved at 13 month F/U | Xu, 2010 | |
| HDMP + R 1 g/m2 × 5d + R weekly × 4 (median 1 cycle) | 37 | 78 | 22 | Bowen, 2007 | 56% (9 patients) | |
| HDMP + R as above × 3 cycles | 14 | 93 | 36 | 15 months | Castro, 2008 | 1 nodular PR |
| HDMP + R 1g/m2 × 5d + R 375 mg/m2 d1 q 28 days | 14 | 93 | 14 | 7 months | Dungarwalla, 2008 | 0% (1 patient) |
| HDMP + R 1st line 1 g/m2 × 3 d | 28 | 96 | 32 | Castro, 2009 |
CR, complete response rate; F/U, followup; HDMP, high-dose methylprednisolone; ORR, overall response rate; PFS, progression-free survival; PR, partial response; R, rituximab; Pt No., patient number.